Auris Medical (EARS) Sets New 12-Month Low at $0.75

Auris Medical Holding AG (NASDAQ:EARS) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $0.75 and last traded at $0.80, with a volume of 708 shares traded. The stock had previously closed at $0.80.

Separately, ValuEngine upgraded Auris Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

The company has a debt-to-equity ratio of -3.12, a current ratio of 1.40 and a quick ratio of 1.40.

Auris Medical (NASDAQ:EARS) last released its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

A number of large investors have recently added to or reduced their stakes in EARS. Virtu Financial LLC acquired a new position in Auris Medical during the fourth quarter worth $129,000. Sabby Management LLC acquired a new position in Auris Medical during the first quarter worth $549,000. Finally, Sofinnova Ventures Inc acquired a new position in Auris Medical during the first quarter worth $1,251,000. Institutional investors own 25.97% of the company’s stock.

Auris Medical Company Profile

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply